In 2023, Michael Greenberg (Harvard, USA), Erin Schuman (Max Planck Institute for Brain Research, Germany) and Christine Holt (University of Cambridge, UK) were awarded The Brain Prize for their pioneering work on activity-dependent gene transcription and local mRNA translation. In this webinar, all 3 Brain Prize winners will present their work. Each speaker will present for 25 minutes and the webinar will conclude with an open discussion. The webinar will be moderated by Kelsey Martin from the Simons Foundation.

Inflammation is a key component of the innate immune response. Primarily designed to remove noxious agents and limit their detrimental effects, the prolonged and/or inappropriately scaled innate immune response may be detrimental to the host and lead to a chronic disease. Indeed, there is increasing evidence suggesting that a chronic deregulation of immunity may represent one of the key elements in the pathobiology of many brain disorders. Microglia are the principal immune cells of the brain. The consensus today is that once activated microglia/macrophages can acquire a wide repertoire of profiles ranging from the classical pro-inflammatory to alternative and protective phenotypes. Recently, we described a novel ribosome-based regulatory mechanism/checkpoint that controls innate immune gene translation and microglial activation involving RNA binding protein SRSF3. Here we will discuss the implications of SRSF3 and other endogenous immune regulators in deregulation of immunity observed in different models of brain pathologies. Furthermore, we will discuss whether targeting SRSF3 and mRNA translation may open novel avenues for therapeutic modulation of immune response in the brain.